Lou Weiyang, Liu Jingxing, Gao Yanjia, Zhong Guansheng, Chen Danni, Shen Jiaying, Bao Chang, Xu Liang, Pan Jie, Cheng Junchi, Ding Bisha, Fan Weimin
Program of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Zhejiang University, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou 310003, China.
Department of Intensive Care Unit, Changxing People's Hospital of Zhejiang, Zhejiang Province, Huzhou 313100, China.
Oncotarget. 2017 Dec 11;8(70):115787-115802. doi: 10.18632/oncotarget.23115. eCollection 2017 Dec 29.
Cancer metastasis is a malignant process by which tumor cells migrate from their primary site of origin to other organs. It is the main cause of poor prognosis in cancer patients. Angiogenesis is the process of generating new blood capillaries from pre-existing vasculature. It plays a vital role in primary tumor growth and distant metastasis. MicroRNAs are small non-coding RNAs involved in regulating normal physiological processes as well as cancer pathogenesis. They suppress gene expression by specifically binding to the 3'-untranslated region (3'-UTR) of their target genes. They can thus act as oncogenes or tumor suppressors depending on the function of their target genes. MicroRNAs have shown great promise for use in anti-metastatic cancer therapy. In this article, we review the roles of various miRNAs in cancer angiogenesis and metastasis and highlight their potential for use in future therapies against metastatic cancer.
癌症转移是一个恶性过程,肿瘤细胞通过该过程从其原发部位迁移至其他器官。它是癌症患者预后不良的主要原因。血管生成是从已有的脉管系统生成新的毛细血管的过程。它在原发性肿瘤生长和远处转移中起着至关重要的作用。微小RNA是参与调节正常生理过程以及癌症发病机制的小非编码RNA。它们通过特异性结合其靶基因的3'非翻译区(3'-UTR)来抑制基因表达。因此,根据其靶基因的功能,它们可以作为癌基因或肿瘤抑制因子。微小RNA在抗转移癌症治疗中显示出巨大的应用前景。在本文中,我们综述了各种微小RNA在癌症血管生成和转移中的作用,并强调了它们在未来转移性癌症治疗中的应用潜力。